Australian Clinical Labs Ltd
ASX:ACL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.16
3.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ACL stock under the Base Case scenario is 4.89 AUD. Compared to the current market price of 3.5 AUD, Australian Clinical Labs Ltd is Undervalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Australian Clinical Labs Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ACL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Australian Clinical Labs Ltd
Balance Sheet Decomposition
Australian Clinical Labs Ltd
Current Assets | 133.6m |
Cash & Short-Term Investments | 26.8m |
Receivables | 81.4m |
Other Current Assets | 25.3m |
Non-Current Assets | 459.5m |
Long-Term Investments | 2.1m |
PP&E | 281.7m |
Intangibles | 164.9m |
Other Non-Current Assets | 10.7m |
Current Liabilities | 207.7m |
Accounts Payable | 53m |
Other Current Liabilities | 154.7m |
Non-Current Liabilities | 207.8m |
Long-Term Debt | 204.2m |
Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
Australian Clinical Labs Ltd
Revenue
|
696.4m
AUD
|
Cost of Revenue
|
-119.3m
AUD
|
Gross Profit
|
577m
AUD
|
Operating Expenses
|
-519.1m
AUD
|
Operating Income
|
57.9m
AUD
|
Other Expenses
|
-34m
AUD
|
Net Income
|
23.9m
AUD
|
Free Cash Flow Analysis
Australian Clinical Labs Ltd
AUD | |
Free Cash Flow | AUD |
ACL Profitability Score
Profitability Due Diligence
Australian Clinical Labs Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Australian Clinical Labs Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
ACL Solvency Score
Solvency Due Diligence
Australian Clinical Labs Ltd's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Score
Australian Clinical Labs Ltd's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACL Price Targets Summary
Australian Clinical Labs Ltd
According to Wall Street analysts, the average 1-year price target for ACL is 3.59 AUD with a low forecast of 2.98 AUD and a high forecast of 4.2 AUD.
Dividends
Current shareholder yield for ACL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ACL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Australian Clinical Labs Ltd. provides pathology services. The company is headquartered in Melbourne, Victoria and currently employs 2,794 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in private hospital pathology businesses in regions of Western Australia, Victoria, South Australia and the Northern Territory. Its brands include Australian Clinical Labs, SunDoctors, Helix Pathology, Southern Sun, BeFunctional Labs and Gribbles Veterinary Pathology. The Australian Clinical Labs provides pathology in Australia, servicing clinicians, patients, hospitals, commercial clients and public organizations. The SunDoctors offers diagnosis and treatment of skin cancer. The Helix Pathology delivers specialized histopathology and cytology testing services. The Southern Sun is the skin cancer lab and the commercial lab in Australia. The BeFunctional Labs assists practitioners in the diagnosis, treatment and management of patients by providing functional pathology tests. The Gribbles Veterinary Pathology provides animal health professionals with pathology service.
Contact
IPO
Employees
Officers
The intrinsic value of one ACL stock under the Base Case scenario is 4.89 AUD.
Compared to the current market price of 3.5 AUD, Australian Clinical Labs Ltd is Undervalued by 28%.